{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:01:44Z","timestamp":1793469704005,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.semradonc.2018.11.006","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T02:31:29Z","timestamp":1551321089000},"page":"166-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management"],"prefix":"10.1016","volume":"29","author":[{"given":"Evan J.","family":"Wuthrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Chablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2018.11.006_bib0001","first-page":"892","article-title":"Melanoma Sentinel-Node Metastasis","volume":"377","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0002","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0003","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0004","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1755-148X.2012.00975.x","article-title":"Reviewing the somatic genetics of melanoma: from current to future analytical approaches","volume":"25","author":"Dutton-Regester","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0006","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"De Luca","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0007","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0008","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0009","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/humu.20481","article-title":"Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants","volume":"28","author":"Hocker","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0010","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0011","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0012","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0013","first-page":"27","article-title":"Genotyping of cutaneous melanoma","volume":"3","author":"Glitza","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0014","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma","volume":"126","author":"Goel","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0015","doi-asserted-by":"crossref","first-page":"2301s","DOI":"10.1158\/1078-0432.CCR-05-2518","article-title":"Genetic alterations in signaling pathways in melanoma","volume":"12","author":"Haluska","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0016","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0017","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0018","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0019","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0020","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0021","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0022","unstructured":"National Cancer Institute, \u201cHigh-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,\u201d ClinicalTrials.gov NCT02506153, 2015."},{"key":"10.1016\/j.semradonc.2018.11.006_bib0023","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0024","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0026","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0027","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0360-3016(99)00431-9","article-title":"Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy","volume":"46","author":"Lee","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0028","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cncr.11243","article-title":"Adjuvant irradiation for cervical lymph node metastases from melanoma","volume":"97","author":"Ballo","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0029","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0360-3016(01)02742-0","article-title":"Adjuvant irradiation for axillary metastases from malignant melanoma","volume":"52","author":"Ballo","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0030","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1245\/ASO.2004.12.039","article-title":"A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma","volume":"11","author":"Ballo","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0031","doi-asserted-by":"crossref","first-page":"4052-9","DOI":"10.1245\/s10434-014-4356-4","article-title":"Patterns of Recurrence in Patients with Stage IIIB\/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?","volume":"22","author":"Barbour","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0032","doi-asserted-by":"crossref","first-page":"473","DOI":"10.6004\/jnccn.2017.0047","article-title":"Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma","volume":"15","author":"Strom","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0033","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1002\/cncr.24627","article-title":"The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma","volume":"115","author":"Agrawal","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0034","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","article-title":"Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial","volume":"13","author":"Burmeister","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0035","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0036","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.ijrobp.2008.06.1910","article-title":"Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma","volume":"73","author":"Beadle","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0037","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ijrobp.2006.05.056","article-title":"Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation","volume":"66","author":"Chang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0038","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0360-3016(91)90053-7","article-title":"Fraction size in external beam radiation therapy in the treatment of melanoma","volume":"20","author":"Sause","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2018.11.006_bib0039","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00249-014-1000-y","article-title":"Nano-characterization of two closely related melanoma cell lines with different metastatic potential","volume":"44","author":"Gostek","year":"2015","journal-title":"Eur Biophys J"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429618301024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429618301024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T11:58:22Z","timestamp":1556366302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429618301024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1053429618301024"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2018.11.006","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}